SynthesisNeurosurgical review2026
Efficacy and safety of MRI-guided focused ultrasound lesioning for tremor-dominant Parkinson Disease: A systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical outcomes at 6 months after MRgFUS thalamotomy in Parkinson's disease: a large longitudinal cohort study.Journal of neurology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objctives Tremor-dominant Parkinson’s disease (TD-PD) remains challenging to manage when symptoms persist despite optimized mediecal therapy. MRI-guided focused ultrasound (MRgFUS) lesioning has emerged as a non-invasive treatment option for medically refractory tremor. To evaluate the efficacy and safety of MRgFUS lesioning specifically in adults with TD-PD. Methods The systematic review and meta-analysis included 16 studies of adult patients with TD-PD who received MRgFUS lesioning targeting the ventral intermediate nucleus (Vim) of the thalamus or the subthalamic nucleus (STN), conducted using RevMan 5.4. Extracted data included tremor scores, UPDRS motor scores, and reported adverse events. Comprehensive searches of PubMed, Scopus, Web of Science, Embase, and Google Scholar were performed to identify peer-reviewed articles published from 2010 to 2025. Results MRgFUS lesioning significantly improved tremor and UPDRS scores. Tremor scores improved in the short-term (< 6 months; pooled SMD = 2.03 [1.35–2.71], I² = 0%) and long-term (> 6 months; pooled SMD = 1.23 [0.82–1.64], I² = 0%), with an overall pooled SMD of 1.50 [1.03–1.98], I² = 41%. UPDRS scores also improved significantly (< 6 months SMD = 1.56 [0.95–2.16], I² = 0%; > 6 months SMD = 0.75 [0.41–1.09], I² = 11%; overall SMD = 0.97 [0.60–1.34], I² = 36%). Sensitivity analyses confirmed the robustness fo these findings. Adverse events were mostly mild-to-moderate, including gait, sensory, speech, limb, facial, and tongue-related disturbances; ≤19% persisted long-term. Conclusion MRgFUS lesioning is a safe and effective treatment for TD-PD, providing substantial short-term and long-term tremor improvements and significant UPDRS score improvements, with mostly mild, transient adverse effects.
Indexed as
Identifiers
41995995What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.